1. **Specific Clinical Study Evidence**

|  |  |  |
| --- | --- | --- |
| Target (Uniprot IDs) | Candidate drugs  (DrugBank IDs) | Clinical study's identifier |
| Nitric oxide synthase,  inducible  (P35228) | Dexamethasone (DB01234) | NCT04366115 |
| Minocycline (DB01017) | IRCT20081019001369N4 |
| Ketamine (DB01221) | NCT04365985 |
| Valproic acid (DB00313) | NCT04513314 |
| Vitamin A (DB00162) | IRCT20200405046951N1 |
| Prostaglandin G/H synthase 1  (P23219) | Ibuprofen (DB01050) | NCT04334629 |
| Peroxisome proliferator-  activated receptor alpha  (Q07869) | Indomethacin (DB00328) | NCT04410536 |
| Tamoxifen (DB00675) | NCT04568096 |
| Fenofibrate (DB01039) | NCT04517396 |
| Peroxisome proliferator-  activated receptor gamma  (P37231) | Amiodarone (DB01118) | EUCTR2020-001951-42-PL |
| Glutamate receptor  ionotropic, NMDA 1  (Q05586) | Ethanol (DB00898) | NCT04554433 |
| Tramadol (DB00193) | NCT04454307 |
| Mu-type opioid receptor  (P35372) | Oxycodone (DB00497) | IRCT20150107020592N24 |
| Naltrexone (DB00704) | NCT04365985 |
| Glucocorticoid receptor  (P04150) | Progesterone (DB00396) | NCT04365127 |
| Spironolactone (DB00421) | NCT04424134 |
| Methylprednisolone (DB00959) | NCT04528888 |
| Budesonide (DB01222) | NCT04374474 |
| Nuclear receptor subfamily 1  group I member 2  (O75469) | Estradiol (DB00783) | NCT04359329 |
| Nifedipine (DB01115) | ChiCTR2000032314 |
| Ritonavir (DB00503) | NCT04455958 |
| G protein-activated inward  rectifier potassium channel 1  (P48549) | Verapamil (DB00661) | EUCTR2020-001951-42-PL |
| Isoflurane (DB00753) | NCT04415060 |
| Histone deacetylase 1  (Q13547) | Simvastatin (DB00641) | NCT04343001 |
| Arsenic trioxide (DB01169) | CTRI/2020/06/025998 |
| Atorvastatin (DB01076) | NCT04466241 |